Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 524 2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

JamesOrzechowski955 Feb. 21 at 8:08 AM

$XLO XLO crypto-linked or derivative exposure. Highly volatile and speculative. Not long-term suitable.

1 · Reply

ezimon Feb. 19 at 10:58 AM

$XLO Total BS but your metaphors are uglier than sexism on steroids

2 · Reply

AskSmacker Feb. 18 at 8:50 PM

$XLO that spread is tighter than a virgin on prom night.

1 · Reply

biohuntress Feb. 17 at 11:34 PM

$XLO Bain added https://xiliotx.gcs-web.com/node/9011/html

0 · Reply

biohuntress Feb. 17 at 11:28 PM

$XLO Gilead hanging in there......over 40M shares total https://xiliotx.gcs-web.com/node/9016/html

1 · Reply

AskSmacker Feb. 17 at 9:18 PM

$XLO which one of you is Adam? too funny

2 · Reply

LabPsycho Feb. 17 at 6:48 PM

$XLO @biohuntress I get the incongruous feeling that one morning some folks holding this seemingly never ending dilution machine are going to be looking at a 130% instant profit. But from what bottom?

1 · Reply

biohuntress Feb. 17 at 4:16 PM

$XLO Stempoint https://xiliotx.gcs-web.com/node/9006/html

1 · Reply

PrivateWealthPro Feb. 17 at 12:25 PM

$XLO Pre-revenue biotech; early-stage with binary outcomes.

1 · Reply

biohuntress Feb. 13 at 10:37 PM

$XLO Frazier https://xiliotx.gcs-web.com/node/9001/html

1 · Reply

Xilio Therapeutics Announces Pricing of Underwritten Offering

Jan 8, 2026, 8:30 AM EST - 6 weeks ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Nov 13, 2025, 7:30 AM EST - 3 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 11, 2025, 4:04 AM EST - 3 months ago

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Nov 7, 2025, 9:05 AM EST - 3 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 3 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 3, 2025, 4:30 PM EST - 4 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 30, 2025, 9:01 AM EDT - 4 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 5 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Sep 9, 2025, 7:30 AM EDT - 6 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Jul 2, 2025, 4:30 PM EDT - 8 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 9 months ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 9 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 9 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 6:11 AM EDT - 9 months ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 9 months ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 10 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 4:30 PM EDT - 10 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:30 PM EDT - 10 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 1 year ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 7:35 AM EST - 1 year ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 1 year ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 2 years ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Oct 31, 2023, 9:15 AM EDT - 2 years ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 2 years ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

JamesOrzechowski955 Feb. 21 at 8:08 AM

$XLO XLO crypto-linked or derivative exposure. Highly volatile and speculative. Not long-term suitable.

1 · Reply

ezimon Feb. 19 at 10:58 AM

$XLO Total BS but your metaphors are uglier than sexism on steroids

2 · Reply

AskSmacker Feb. 18 at 8:50 PM

$XLO that spread is tighter than a virgin on prom night.

1 · Reply

biohuntress Feb. 17 at 11:34 PM

$XLO Bain added https://xiliotx.gcs-web.com/node/9011/html

0 · Reply

biohuntress Feb. 17 at 11:28 PM

$XLO Gilead hanging in there......over 40M shares total https://xiliotx.gcs-web.com/node/9016/html

1 · Reply

AskSmacker Feb. 17 at 9:18 PM

$XLO which one of you is Adam? too funny

2 · Reply

LabPsycho Feb. 17 at 6:48 PM

1 · Reply

biohuntress Feb. 17 at 4:16 PM

$XLO Stempoint https://xiliotx.gcs-web.com/node/9006/html

1 · Reply

PrivateWealthPro Feb. 17 at 12:25 PM

$XLO Pre-revenue biotech; early-stage with binary outcomes.

1 · Reply

biohuntress Feb. 13 at 10:37 PM

$XLO Frazier https://xiliotx.gcs-web.com/node/9001/html

1 · Reply

biohuntress Feb. 12 at 9:49 PM

$XLO Gilead https://xiliotx.gcs-web.com/node/8986/html

2 · Reply

8AA Feb. 12 at 9:04 PM

$XLO pump when market is down is really a opportunity to buy. or just insider manipulation. who knows. risky as shit. please buy and make some rich man same money, their really need it.

0 · Reply

809trader Feb. 12 at 8:51 PM

$XLO Boooooom baby!!!

0 · Reply

ThirstyFishy Feb. 12 at 8:50 PM

$XLO what's going on???

0 · Reply

ezimon Feb. 12 at 4:54 PM

$XLO either RS or delisting will go ahead. By April people can pick up todays shares for .10 instead of .50 all you need to do is wait a couple of months

1 · Reply

biovaluable Feb. 12 at 3:34 PM

$XLO Don't They Already Have Enough Cash? Why Did They Offer?

1 · Reply

809trader Feb. 12 at 2:46 PM

$XLO this offering and their buyers can’t be more bullish. Gilead about to buy this puppy rest of the shares pretty soon. I see this puppy running to 0.75 in no time.

1 · Reply

LabPsycho Feb. 12 at 2:30 PM

$XLO BioGrifter's Creed: We can never have enough of investors (saps) money. We will dilute as our stock approaches historic lows We will dilute massively on any news. When positive news dries up, We will dilute massively again, even on no news. When it seems our stuff aint working, it doesnt matter, We just want more of your money and make up a story and use words to describe disappointing clinical data like "compelling" and "cash runway" to dupe investors giving them false hopes that the stuff might work and no need to worry about a dilution anytime soon - then dilute anyway. Thank you for paying for our inflated salaries and generous benefits. https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-pricing-underwritten-offering

1 · Reply

809trader Feb. 12 at 2:27 PM

$XLO buying another 20k shares today. Gilead cant buy enough. LFG

0 · Reply

LabPsycho Feb. 12 at 2:10 PM

$XLO @Doom_Gloom_AR @Scooter0732 @LabPsycho @Oll1koo This is what I would like to see - I am just waiting for a R/S, a 30% drop after that, volume to dry up as stock plateaus down for a couple of months, then maybe move it up on my list. If it wasnt for their history of massive dilutions, I would say there is a good chance of 150% bounce on this off the bottom - but where is the bottom? Not here IMO. I think biotechs are going to dry up for 6 weeks then a few will run up to ASCO meeting - and there likely will be one surprise sleeper company (not on my list) that will suck a few back into biotechs for a few weeks. Good luck

0 · Reply

MarketReaper Feb. 12 at 10:35 AM

$XLO Vilastobart data must be good if Gilead are buying more shares, are they getting ready for a BIG announcement and hoping to get over $1 for 10 days before the deadline? Or will the RS go ahead?

0 · Reply

Biotech_Pharma_Investor Feb. 12 at 5:54 AM

$XLO Vilastobart is supposed to be safer than ipi with (probably) better efficacy. I don't see why they havent tried developing against ipi in head-to-head trials in approved ipi indications (even non-inferiority but better safety would be a great outcome). Goal would be to replace ipi. Have they already tried this? Trying to expand to harder tumors is riskier @LabPsycho @Scooter0732

0 · Reply

Market Cap	37.24M
Revenue (ttm)	6.34M
Net Income (ttm)	-58.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-918.61%
Debt to Equity Ratio	0.00

Volume	504,400
Avg Vol	451,538
Day's Range	N/A - N/A
Shares Out	67.54M
Stochastic %K	42%
Beta	-0.06
Analysts	Sell
Price Target	$2.00